Lexeo Therapeutics, Inc. (LXEO) AI Stock Analysis

• Market Cap: $563.46M
• Dividend Yield: N/A
• Average Volume (3M): 1.48M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.98
• Revenue Growth: N/A
• EPS Growth: 4.97%
• Country: US
• Employees: 75
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 72,987,330
• 10 Day Avg. Volume: 1,614,664
• 30 Day Avg. Volume: 1,484,057
• PEG Ratio: -0.09
• Price to Book (P/B): 1.79
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.56
• Enterprise Value/Market Cap: 0.52
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -188.58
• Enterprise Value/Ebitda: -2.83
• 1Y Price Target: $18.17
• Price Target Upside: 135.32% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -1.57
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: $11.00 ▲(42.49% Upside)

Score is held back primarily by weak financial performance (no revenue, widening losses, and very high cash burn), partially offset by a conservative balance sheet, constructive technical uptrend, and positive clinical/capital-raise corporate updates.

Positive Factors

Regulatory Progress

Advancing FDA discussions for LX2006 could expedite approval, enhancing Lexeo's market entry and competitive position in gene therapy for cardiac conditions.

Clinical Pipeline Momentum

Positive clinical data for LX2006 suggests potential for breakthrough therapies, strengthening Lexeo's pipeline and long-term growth prospects in genetic cardiomyopathy.

Financial Strengthening

The $135M capital raise provides financial resources to support ongoing R&D and commercialization efforts, reducing near-term funding risks and enabling strategic initiatives.

Negative Factors

Cash Burn

Sustained negative cash flow indicates high operational costs without revenue, pressuring financial stability and necessitating ongoing capital raises to fund operations.

Pre-Revenue Status

Being pre-revenue with widening losses highlights the risk of prolonged financial dependency on external funding, challenging Lexeo's path to profitability.

Funding Risk

Continuous losses without revenue generation increase the risk of needing further capital, potentially diluting shareholder value and impacting long-term financial health.

Lexeo Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

How the Company Makes Money

Lexeo Therapeutics, Inc. generates revenue primarily through the development and commercialization of its gene therapy products. The company may earn income from licensing agreements, research and development collaborations, and partnerships with pharmaceutical companies. Additionally, Lexeo may receive funding through grants, government contracts, or milestone payments related to the clinical progression and commercialization of its therapies. Strategic alliances and partnerships with larger pharmaceutical companies could also contribute to Lexeo's revenue stream, providing access to broader distribution networks and additional resources for product development.

Lexeo Therapeutics, Inc. Financial Statement Overview

Summary

Lexeo Therapeutics faces significant operational risks with no revenue and growing losses, as reflected by its income statement. While the balance sheet shows improved equity positions, high liabilities remain a concern. The cash flow situation indicates a heavy reliance on external financing, posing long-term sustainability risks.

Income Statement

Over the last five years, Lexeo Therapeutics has consistently reported no revenue, highlighting the challenges in revenue generation typical in the biotech industry. The company has faced substantial net losses, with a deteriorating net income trend from -$5.15 million in 2020 to -$98.33 million in 2024. The absence of EBIT and EBITDA margins further underscores the company's struggle to achieve profitability. This trend indicates a high-risk profile with substantial room for improvement in operational efficiency and revenue generation.

Balance Sheet

Lexeo Therapeutics maintains a relatively strong equity position with stockholders' equity increasing from a negative position in 2020 to $116.84 million in 2024. The debt-to-equity ratio has improved due to reduced liabilities and increased equity, indicating prudent financial management. However, the company’s total assets have only seen modest growth, limiting its expansion potential. The equity ratio is positive, but the high liabilities relative to assets remain a concern.

Cash Flow

The cash flow statement shows a consistent trend of negative operating cash flow, with a significant increase in cash outflow from operations in 2024 compared to previous years. Free cash flow remains negative, indicating ongoing challenges in cash generation. The company relies heavily on financing activities, as seen from the positive financing cash flows, to sustain its operations. This reliance poses risks if external funding sources diminish.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	654.00K	1.66M	518.48K
Gross Profit	-1.54M	0.00	0.00	654.00K	1.66M	518.48K
EBITDA	-102.75M	-96.19M	-64.35M	-58.04M	-50.61M	-4.59M
Net Income	-104.97M	-98.33M	-66.39M	-59.28M	-50.62M	-5.15M
Balance Sheet
Total Assets	143.84M	146.94M	139.81M	97.08M	136.86M	29.41M
Cash, Cash Equivalents and Short-Term Investments	41.00M	121.52M	121.47M	77.33M	135.86M	29.37M
Total Debt	8.46M	9.92M	11.64M	13.48M	0.00	0.00
Total Liabilities	23.01M	30.10M	26.27M	210.03M	192.46M	34.95M
Stockholders Equity	120.83M	116.84M	113.53M	-112.95M	-55.60M	-5.54M
Cash Flow
Free Cash Flow	-107.19M	-81.63M	-59.66M	-55.46M	-44.37M	-3.13M
Operating Cash Flow	-106.81M	-81.15M	-59.50M	-54.56M	-44.18M	-3.13M
Investing Cash Flow	-82.15M	-94.08M	-165.00K	-901.00K	-188.00K	0.00
Financing Cash Flow	72.93M	88.78M	103.79M	189.00K	150.86M	32.38M

Lexeo Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.72
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LXEO, the sentiment is Negative. The current price of 7.72 is below the 20-day moving average (MA) of 9.53, below the 50-day MA of 9.31, and above the 200-day MA of 5.93, indicating a neutral trend. The MACD of -0.40 indicates Positive momentum. The RSI at 36.25 is Neutral, neither overbought nor oversold. The STOCH value of 16.88 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LXEO.

Lexeo Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LXEO	58 Neutral	$563.46M	-2.78	-80.69%	―	―	4.97%
CAPR	57 Neutral	$1.35B	-13.37	-107.79%	―	-52.08%	-69.35%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DMAC	49 Neutral	$447.87M	-11.91	-64.12%	―	―	-29.73%
BNTC	48 Neutral	$410.75M	-11.65	-43.71%	―	―	80.95%
LRMR	45 Neutral	$291.86M	-1.69	-78.24%	―	―	-67.41%
TVRD	38 Underperform	$43.44M	-0.46	-97.61%	―	-53.67%	86.75%

Lexeo Therapeutics, Inc. Corporate Events

Lexeo Therapeutics Reports Positive Interim HEROIC-PKP2 Trial Results

On January 12, 2026, Lexeo Therapeutics reported positive interim Phase I/II data from its HEROIC-PKP2 trial evaluating LX2020, an AAV-based gene therapy for PKP2-associated arrhythmogenic cardiomyopathy, showing the treatment was generally well tolerated in ten dosed participants with no clinically significant complement activation and no study discontinuations. Cardiac biopsies from seven participants demonstrated robust, dose-dependent PKP2 transduction and expression, with mean PKP2 protein levels rising 93% in the low-dose cohort and 162% in the high-dose cohorts, and clinical measures in eight participants with at least six months of follow-up indicated stabilization or improvement in arrhythmia burden, including reductions in non-sustained ventricular tachycardia and premature ventricular contractions, alongside stable cardiac function and improved patient-reported outcomes at higher doses. Enrollment in HEROIC-PKP2 was completed in the fourth quarter of 2025, with additional biopsy data and 12‑month outcomes from high-dose participants expected in 2026, positioning LX2020 as a potentially important new therapy candidate in a genetically driven cardiomyopathy segment with significant unmet need and reinforcing Lexeo’s strategic focus on gene therapy for cardiovascular disease.

The most recent analyst rating on (LXEO) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Lexeo Therapeutics, Inc. stock, see the LXEO Stock Forecast page.

Lexeo Therapeutics Announces $135M Public Offering

On October 16, 2025, Lexeo Therapeutics announced the pricing of its public offering and concurrent private placement, expected to raise approximately $135 million before expenses. The public offering involves 15,625,000 shares at $8.00 per share, with an option for underwriters to purchase additional shares, while the private placement involves pre-funded warrants. The proceeds will support the company’s operations and development programs. Additionally, Lexeo provided updates on its LX2006 and LX2020 clinical programs, highlighting progress in regulatory interactions with the FDA and ongoing clinical trials. The LX2006 program is exploring accelerated approval pathways with the FDA, while the LX2020 trial is progressing with positive interim safety and efficacy data.

The most recent analyst rating on (LXEO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Lexeo Therapeutics, Inc. stock, see the LXEO Stock Forecast page.